Natixis Advisors LLC Sells 58,301 Shares of Takeda Pharmaceutical Co. (NYSE:TAK)

Key Points

• Natixis Advisors LLC reduced its stake in Takeda Pharmaceutical Co. by 12.2%, selling 58,301 shares and leaving them with a total of 420,278 shares valued at approximately $6.25 million.
• Despite Natixis's sale, other institutional investors increased their holdings, with GAMMA Investing LLC raising their stake by 22.6% and Russell Investments Group Ltd. increasing theirs by 48.6%.
• Takeda Pharmaceutical's shares were trading at $14.30, having a market cap of $45.49 billion, and reported an earnings per share (EPS) of $0.52 for the last quarter.

Natixis Advisors LLC lessened its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 12.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 420,278 shares of the company's stock after selling 58,301 shares during the period. Natixis Advisors LLC's holdings in Takeda Pharmaceutical were worth $6,250,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. FNY Investment Advisers LLC acquired a new position in shares of Takeda Pharmaceutical during the 1st quarter worth about $37,000. Farther Finance Advisors LLC lifted its stake in Takeda Pharmaceutical by 29.2% in the first quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock valued at $69,000 after acquiring an additional 1,045 shares during the last quarter. Fifth Third Bancorp grew its position in shares of Takeda Pharmaceutical by 85.5% in the 1st quarter. Fifth Third Bancorp now owns 5,232 shares of the company's stock valued at $78,000 after acquiring an additional 2,411 shares during the period. Point72 Hong Kong Ltd acquired a new position in shares of Takeda Pharmaceutical during the 4th quarter worth about $94,000. Finally, GAMMA Investing LLC raised its holdings in shares of Takeda Pharmaceutical by 22.6% in the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company's stock valued at $105,000 after purchasing an additional 1,296 shares during the period. Institutional investors and hedge funds own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Performance

Takeda Pharmaceutical stock traded up $0.12 during midday trading on Thursday, reaching $14.39. 4,534,287 shares of the company's stock were exchanged, compared to its average volume of 2,513,440. The stock's 50-day simple moving average is $14.84 and its 200 day simple moving average is $14.54. The firm has a market cap of $45.77 billion, a price-to-earnings ratio of 47.95 and a beta of 0.22. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.59 and a current ratio of 1.16. Takeda Pharmaceutical Co. has a 52 week low of $12.80 and a 52 week high of $15.53.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. The company had revenue of $7.45 billion during the quarter, compared to analysts' expectations of $7.96 billion. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. On average, analysts expect that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.